Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CytomX Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding CytomX Therapeutics, Inc.’s stock price such as:

• CytomX Therapeutics, Inc.’s current stock price and volume
• Why CytomX Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CTMX from analysts
• CTMX’s stock price momentum as measured by its relative strength

About CytomX Therapeutics, Inc. (CTMX)

Before we jump into CytomX Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Want to learn more about CytomX Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about CytomX Therapeutics, Inc..

CytomX Therapeutics, Inc.’s Stock Price as of Market Close

As of February 25, 2026, 3:47 PM, CST, CytomX Therapeutics, Inc.’s stock price was $5.730.

CytomX Therapeutics, Inc. is up 5.33% from its previous closing price of $5.440.

During the last market session, CytomX Therapeutics, Inc.’s stock traded between $5.476 and $6.100. Currently, there are approximately 165.00 million shares outstanding for CytomX Therapeutics, Inc..

CytomX Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 22.7, which is high compared to the Biotechnology industry median of 22.4. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

CytomX Therapeutics, Inc. Stock Price History

CytomX Therapeutics, Inc.’s (CTMX) price is currently up 0.7% so far this month.

During the month of February, CytomX Therapeutics, Inc.’s stock price has reached a high of $6.350 and a low of $5.030.

Over the last year, CytomX Therapeutics, Inc. has hit prices as high as $6.350 and as low as $0.400. Year to date, CytomX Therapeutics, Inc.’s stock is up 34.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused CytomX Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 24, 2026, there was 1 analyst who downgraded CytomX Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate CytomX Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on CytomX Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

CytomX Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about CytomX Therapeutics, Inc. (CTMX) by visiting AAII Stock Evaluator.

Relative Price Strength of CytomX Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 24, 2026, CytomX Therapeutics, Inc. has a weighted four-quarter relative price strength of 69.58%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how CytomX Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

CytomX Therapeutics, Inc. Stock Price: Bottom Line

As of February 25, 2026, CytomX Therapeutics, Inc.’s stock price is $5.730, which is up 5.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like CytomX Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.